期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 83, 期 2, 页码 365-367出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.clpt.6100460
关键词
-
When I was invited to author an ethics policy piece on the approach to high-risk molecules as a contribution to the theme of Innovation in Drug Development of this Clinical Pharmacology & Therapeutics issue, I thought there was a need to evaluate whether questioning the transition from preclinical to clinical development after the TGN 1412 serious adverse event may freeze the development of innovating tools in drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据